- Home
- underscore plus
- ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma - ecancer
ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma - ecancer
4.8 (192) · $ 12.99 · In stock
Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti
ASCO 2022: Pembrolizumab + Axitinib Versus Sunitinib As First-Line Therapy for Advanced Clear Cell RCC: Analysis of Progression After First Subsequent Therapy in KEYNOTE-426
PDF) The use of serial circulating tumor DNA (ctDNA) to detect resistance alterations in progressive metastatic breast cancer
ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426
ASCO 2020: KEYNOTE-426: Pembrolizumab plus Axitinib versus Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial - ScienceDirect
ASCO 2022: Pembrolizumab + Axitinib Versus Sunitinib As First-Line Therapy for Advanced Clear Cell RCC: Analysis of Progression After First Subsequent Therapy in KEYNOTE-426
PDF) Critical Issues in Head and Neck Oncology
ASCO GU 2022: Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Sunitinibin the East Asian Subset of Patients With Advanced Renal Cell Carcinoma From the Phase 3 CLEAR Trial
PDF) The use of serial circulating tumor DNA (ctDNA) to detect resistance alterations in progressive metastatic breast cancer
PDF) Emozioni scoperte: A COLLECTION OF AUTOBIOGRAPHICAL TEXTS BY ONCOLOGIC PATIENTS
ASCO 2019: First-Line Pembrolizumab Monotherapy in Advanced Clear Cell Renal Cell Carcinoma: Updated Results for KEYNOTE-427 Cohort A
ASCO-SEP Medical Oncology Self-Evaluation Program, 7e by ASCO, PDF, Breast Cancer
Abeloff's Clinical Oncology [6 ed.] 0323476740, 9780323476744
Frontiers Role of metastasectomy in the management of renal cell carcinoma
